Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pfizer to boost vaccine production for U.S. by 10%

By Nancy Crotti | April 14, 2021

PfizerPfizer will deliver 10% more of its COVID-19 vaccine to the U.S. by the end of May than originally planned, its CEO tweeted yesterday.

The tweet follows the federal government’s decision to recommend a temporary halt in the distribution of Johnson & Johnson’s single-dose vaccine, which has been tied to rare instances of blood clot formation in women.

Pfizer will deliver 220 million doses of its two-dose vaccine by the end of May and supply the full 300 million it agreed to for the end of July two weeks early, CEO Albert Bourla tweeted. “In the fight against COVID-19, we’re in this together,”  he added.

Pfizer CEO tweetAs of Monday, more than 6.8 million doses of the J&J single-dose vaccine had been administered in the U.S. Among recipients of those doses, six cases of a rare and severe type of blood clot have been reported. The CDC and FDA are reviewing data involving these cases.

Some experts posit that the adenovirus used in J&J’s vaccine may be the culprit behind the formation of a blood clot known as cerebral venous sinus thrombosis (CVST), which federal officials said yesterday was seen in combination with low levels of blood platelets (thrombocytopenia). All six cases were in women between ages 18 and 48. One woman in Virginia has died and another in Nebraska is in critical condition, according to a report by the New York Times.

The CDC is set to convene a meeting of the Advisory Committee on Immunization Practices (ACIP) today to review the cases and assess the potential significance, while the FDA plans to review the analysis as part of its own investigation. Until the reviews conclude, the agencies recommended a pause “out of an abundance of caution,” in part to ensure healthcare providers are aware of the potential for these blood clots and can prepare for the proper recognition and management of such events.

Pfizer has already delivered nearly 123.5 million doses to the U.S., according to the CDC. Of those, 99.5 million have been administered. Moderna has delivered 104.4 million, of which 85.4 million have been administered.

By comparison, J&J has delivered 17.4 million doses of its vaccine to the U.S., of which 7.3 million have been administered, the CDC noted.

 

 


Filed Under: Drug Delivery, Drug Discovery and Development
Tagged With: coronavirus, COVID-19 vaccines, FDA, Johnson & Johnson, Pfizer, U.S. Centers for Disease Control and Prevention (CDC)
 

Related Articles Read More >

A display of DNA sequencing output from an automated ABI 373 sequencer. [National Human Genome Research Institute (NHGRI)]
Helix and Recursion join forces in quest to crack the AI-driven drug discovery code
Ypsomed Ypsodose patch injector
ten23 health to develop large-volume injectables for Ypsomed’s YpsoDose
Shasqi
Click chemistry breakthroughs drive Shasqi and J&J cancer alliance
Shasqi
Nobel-connected startup Shasqi deepens J&J partnership on CAPAC platform
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE